Information Provided By: 
Fly News Breaks for January 6, 2016
GILD, ICPT
Jan 6, 2016 | 07:24 EDT
Oppenheimer analyst Akiva Felt noted that Gilead (GILD) will terminate its Phase 2 trial of simtuzumab in idiopathic pulmonary fibrosis but will continue its two Phase 2 studies of the drug in NASH as planned. The analyst views Gilead's drug, which should have data from the NASH and cirrhotic-NASH trials in Q4, as the most advanced competitive therapy to Intercept's (ICPT) obeticholic acid, but continues to view Intercept's drug as the most likely to succeed. Felt keeps an Outperform rating and $375 price target on Intercept shares.
News For ICPT;GILD From the Last 2 Days
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
